High rate of molecular alteration in histologically tumour-free bronchial epithelium of NSCLC patients detected by multicolour fluorescence in situ hybridisation

Oncology Reports

Volumn 15, Issue 5, 2006, Pages 1233-1240

  Hilbe, Wolfgang ^a   Auberger, Jutta ^a   Dirnhofer, Stephan ^d   Schmid, Thomas ^b   Erdel, Martin ^b   Duba, Hans Christoph ^b,c  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c Department of Human Genetics   (Austria)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Field cancerisation; Fluorescence in situ hybridisation; Lung cancer; Multicolour FISH; Non small cell lung cancer; Screening

Indexed keywords

ADULT; AGED; ARTICLE; BRONCHUS; CHROMOSOME ABERRATION; COMPARATIVE STUDY; DNA PROBE; EPITHELIUM; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; HUMAN CHROMOSOME; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; PATHOLOGY; RESPIRATORY TRACT MUCOSA; TUMOR RECURRENCE;

ADULT; AGED; BRONCHI; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; DNA PROBES; EPITHELIUM; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RESPIRATORY MUCOSA;

EID: 33744975508     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.5.1233     Document Type: Article

References (75)

1. Hilbe W, Dirnhofer S, Greil R and Woll E: Biomarkers in non-small cell lung cancer prevention. Eur J Cancer Prev 13: 425-436, 2004. (Pubitemid 39336608)
2. Wiest JS, Franklin WA, Drabkin H, Gemmill R, Sidransky D and Anderson MW: Genetic markers for early detection of lung cancer and outcome measures for response to chemoprevention. J Cell Biochem Suppl 28: 2964-2973, 1997.
3. Zochbauer-Muller S, Gazdar AF and Minna JD: Molecular pathogenesis of lung cancer. Annu Rev Physiol 64681-64708, 2002.
4. Perez-Soler R, Chachoua A, Hammond LA, et al: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22: 3238-3247, 2004. (Pubitemid 41103678)
5. Fukuoka M, Yano S, Giaccone G, et al : Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL1 Trial) [corrected]. J Clin Oncol 21: 2237-2246, 2003. (Pubitemid 46621858)
6. Mao L, Lee JS, Kurie JM, et al: Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 89: 857-862, 1997. (Pubitemid 27268450)
7. Chung GT, Sundaresan V, Hasleton P, Rudd R, Taylor R and Rabbitts PH: Clonal evolution of lung tumors. Cancer Res 56: 1609-1614, 1996. (Pubitemid 26104025)
8. Niklinski J, Niklinska W, Chyczewski L, Becker HD and Pluygers E: Molecular genetic abnormalities in premalignant lung lesions: biological and clinical implications. Eur J Cancer Prev 10: 213-226, 2001. (Pubitemid 32530365)
9. Kishimoto Y, Sugio K, Hung JY, Virmani AK, McIntire DD, Minna JD and Gazdar AF: Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. J Natl Cancer Inst 87: 1224-1229, 1995.
10. Hung J, Kishimoto Y, Sugio K, Virmani A, McIntire DD, Minna JD and Gazdar AF: Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA 273: 558-563, 1995.
11. Califano J, van der Riet P, Westra W, et al: Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56: 2488-2492, 1996. (Pubitemid 26170679)
12. Smith AL, Hung J, Walker L, Rogers TE, Vuitch F, Lee E and Gazdar AF: Extensive areas of aneuploidy are present in the respiratory epithelium of lung cancer patients. Br J Cancer 73: 203-209, 1996. (Pubitemid 26028335)
13. Lu YJ, Dong XY, Guo SP, et al: 2q-, a non-random chromosomal abnormality in human non-small-cell lung cancer. Carcinogenesis 17: 1589-1593, 1996.
14. Virmani AK, Fong KM, Kodagoda D, et al : Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer 21: 308-319, 1998. (Pubitemid 28165038)
15. Wistuba II, Lam S, Behrens C, et al: Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 89: 1366-1373, 1997. (Pubitemid 27418028)
16. Sozzi G, Veronese ML, Negrini M, et al: The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 85: 17-26, 1996. (Pubitemid 26116803)
17. Mitsudomi T, Oyama T, Nishida K, et al: Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. Clin Cancer Res 2: 1185-1189, 1996. (Pubitemid 26238450)
18. Balsara BR, Sonoda G, du Manoir S, Siegfried JM, Gabrielson E and Testa JR: Comparative genomic hybridization analysis detects frequent, often high-level, overrepresentation of DNA sequences at 3q, 5p, 7p, and 8q in human non-small cell lung carcinomas. Cancer Res 57: 2116-2120, 1997. (Pubitemid 27247023)
19. Greatens TM, Niehans GA, Rubins JB, Jessurun J, Kratzke RA, Maddaus MA and Niewoehner DE: Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med 157: 1093-1097, 1998.
20. Schenk T, Ackermann J, Brunner C, Schenk P, Zojer N, Roka S and Drach J: Detection of chromosomal aneuploidy by interphase fluorescence in situ hybridization in bronchoscopically gained cells from lung cancer patients. Chest 111: 1691-1696, 1997. (Pubitemid 27260104)
21. Taguchi T, Zhou JY, Feder M, Litwin S, Klein-Szanto AJ and Testa JR: Detection of aneuploidy in interphase nuclei from non-small cell lung carcinomas by fluorescence in situ hybridization using chromosome-specific repetitive DNA probes. Cancer Genet Cytogenet 89: 120-125, 1996. (Pubitemid 26286747)
22. Duba HC, Hilbe W, Mehringer A, Erdel M, Thaler J and Utermann G: Hypermetaphase and interphase fluorescence in situ hybridisation for monitoring of remission status in Philadelphia chromosome positive chronic myeloid leukaemia. Int J Oncol 17: 1245-1249, 2000.
23. Fiegl M, Kaufmann H, Zojer N, et al: Malignant cell detection by fluorescence in situ hybridization (FISH) in effusions from patients with carcinoma. Hum Pathol 31: 448-455, 2000. (Pubitemid 30262867)
24. Brambilla E, Travis WD, Colby TV, Corrin B and Shimosato Y: The new World Health Organization classification of lung tumours. Eur Respir J 18: 1059-1068, 2001. (Pubitemid 34092881)
25. Sobin LH and Wittekind C: TNM classification of malignant tumours. 6th edition. 2002.
26. Liehr T, Uwe C and Erich G: Nucleus extraction from single mounted tissue sections. Genet Anal 15: 65-69, 1999. (Pubitemid 29135364)
27. Fiegl M, Haun M, Massoner A, et al: Combination of cytology, fluorescence in situ hybridization for aneuploidy, and reversetranscriptase polymerase chain reaction for human mammaglobin/ mammaglobin B expression improves diagnosis of malignant effusions. J Clin Oncol 22: 474-483, 2004. (Pubitemid 41079777)
28. Duba HC, Erdel M, Loffler J, Wirth J, Utermann B and Utermann G: Nail patella syndrome in a cytogenetically balanced t(9;17)(q34.1;q25) carrier. Eur J Hum Genet 6: 75-79, 1998. (Pubitemid 28101700)
29. Siebert R, Jacobi C, Matthiesen P, et al: Detection of deletions in the short arm of chromosome 3 in uncultured renal cell carcinomas by interphase cytogenetics. J Urol 160: 534-539, 1998. (Pubitemid 29476730)
30. Sekido Y, Fong KM and Minna JD: Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1378: F21-F59, 1998. (Pubitemid 28381125)
31. Braithwaite KL and Rabbitts PH: Multi-step evolution of lung cancer. Semin Cancer Biol 9: 255-265, 1999. (Pubitemid 29429990)
32. Sundaresan V, Ganly P, Hasleton P, Rudd R, Sinha G, Bleehen NM and Rabbitts P: p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene 7: 1989-1997, 1992.
33. Fong KM, Sekido Y, Gazdar AF and Minna JD: Lung cancer 9: Molecular biology of lung cancer: clinical implications. Thorax 58: 892-900, 2003. (Pubitemid 37239240)
34. Thiberville L, Payne P, Vielkinds J, et al: Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus. Cancer Res 55: 5133-5139, 1995.
35. Sozzi G, Pastorino U, Moiraghi L, et al: Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 58: 5032-5037, 1998. (Pubitemid 28521154)
36. Fong KM, Biesterveld EJ, Virmani A, et al: FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res 57: 2256-2267, 1997. (Pubitemid 27247047)
37. Kishimoto Y, Murakami Y, Shiraishi M, Hayashi K and Sekiya T: Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res 52: 4799-4804, 1992.
38. Brambilla E, Gazzeri S, Lantuejoul S, Coll JL, Moro D, Negoescu A and Brambilla C: p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer. Clin Cancer Res 4: 1609-1618, 1998. (Pubitemid 28304721)
39. Takahashi T, Nau MM, Chiba I, et al: p53: a frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. (Pubitemid 19273938)
40. Lemon SJ, Sabichi AL and Birrer MJ: Genetic alterations in lung cancer. Cellular Cancer Markers. Humana Press Inc., pp209-229, 1995.
41. Vega FJ, Iniesta P, Caldes T, et al: p53 exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer. Br J Cancer 76: 44-51, 1997. (Pubitemid 27250074)
42. Jassem J, Jassem E, Jakobkiewicz-Banecka J, et al : P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma. Cancer 100: 1951-1960, 2004. (Pubitemid 38529573)
43. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
44. Ewen ME: The cell cycle and the retinoblastoma protein family. Cancer Metastasis Rev 13: 45-66, 1994.
45. Geradts J, Fong KM, Zimmerman PV, Maynard R and Minna JD: Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res 5: 791-800, 1999. (Pubitemid 29180830)
46. Reissmann PT, Koga H, Takahashi R, et al: Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. Oncogene 8: 1913- 1919, 1993.
47. Cagle PT, El Naggar AK, Xu HJ, Hu SX and Benedict WF: Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Potential diagnostic implications. Am J Pathol 150: 393-400, 1997. (Pubitemid 27073768)
48. Dosaka-Akita H, Hu SX, Fujino M, et al : Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis. Cancer 79: 1329-1337, 1997. (Pubitemid 27143239)
49. Liggett WH Jr and Sidransky D: Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16: 1197-1206, 1998.
50. Xiao S, Li D, Corson JM, Vijg J and Fletcher JA: Co-deletion of p15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res 55: 2968-2971, 1995.
51. Gorgoulis VG, Zacharatos P, Kotsinas A, et al: Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. Am J Pathol 153: 1749-1765, 1998. (Pubitemid 28550663)
52. Okami K, Cairns P, Westra WH, et al : Detailed deletion mapping at chromosome 9p21 in non-small cell lung cancer by microsatellite analysis and fluorescence in situ hybridization. Int J Cancer 74: 588-592, 1997. (Pubitemid 28037499)
53. Sanz-Ortega J, Saez MC, Sierra E, et al: 3p21, 5q21, and 9p21 allelic deletions are frequently found in normal bronchial cells adjacent to non-small-cell lung cancer, while unusual in patients with no evidence of malignancy. J Pathol 195: 429-434, 2001. (Pubitemid 33069667)
54. Doubre H, Cesari D, Mairovitz A, et al: Multidrug resistanceassociated protein (MRP1) is overexpressed in DNA aneuploid carcinomatous cells in non-small cell lung cancer (NSCLC). Int J Cancer 113: 568-574, 2005. (Pubitemid 40038732)
55. Wong MP, Fung LF, Wang E, et al: Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers. Cancer 97: 1263-1270, 2003. (Pubitemid 36237313)
56. Sato M, Mori Y, Sakurada A, Fujimura S and Horii A: The H-cadherin (CDH13) gene is inactivated in human lung cancer. Hum Genet 103: 96-101, 1998. (Pubitemid 28398393)
57. Kuramochi M, Fukuhara H, Nobukuni T, et al : TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet 27: 427-430, 2001. (Pubitemid 32268425)
58. Murakami Y: Functional cloning of a tumor suppressor gene, TSLC1, in human non-small cell lung cancer. Oncogene 21: 6936-6948, 2002.
59. Dai Z, Zhu WG, Morrison CD, et al: A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Hum Mol Genet 12: 791-801, 2003. (Pubitemid 36416965)
60. Romeo MS, Sokolova IA, Morrison LE, et al: Chromosomal abnormalities in non-small cell lung carcinomas and in bronchial epithelia of high-risk smokers detected by multi-target interphase fluorescence in situ hybridization. J Mol Diagn 5: 103-112, 2003. (Pubitemid 36553430)
61. Kurie JM, Shin HJ, Lee JS, et al: Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 2: 1787-1793, 1996. (Pubitemid 26356366)
62. Hilbe W, Dlaska M, Dirnhofer S, et al : Characterisation and predictive value of epidermal growth factor receptor status using quantitative real-time PCR combined with immunohistochemistry on non-small cell lung cancer specimens. Int J Oncol 23: 893-899, 2003.
63. Sokolova IA, Bubendorf L, O'Hare A, et al: A fluorescence in situ hybridization-based assay for improved detection of lung cancer cells in bronchial washing specimens. Cancer 96: 306-315, 2002. (Pubitemid 35221619)
64. Kerr KM: Pulmonary preinvasive neoplasia. J Clin Pathol 54: 257-271, 2001.
65. Spira A, Beane J, Shah V, et al: Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc Natl Acad Sci USA 101: 10143-10148, 2004. (Pubitemid 38891209)
66. Baksh FK, Dacic S, Finkelstein SD, et al: Widespread molecular alterations present in stage I non-small cell lung carcinoma fail to predict tumor recurrence. Mod Pathol 16: 28-34, 2003. (Pubitemid 36152683)
67. De Juan C, Iniesta P, Vega FJ, et al : Prognostic value of genomic damage in non-small-cell lung cancer. Br J Cancer 77: 1971-1977, 1998. (Pubitemid 28254642)
68. De Anta JM, Jassem E, Rosell R, et al: TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis. Oncogene 15: 2951-2958, 1997. (Pubitemid 28008987)
69. Liloglou T, Maloney P, Xinarianos G, et al: Cancer-specific genomic instability in bronchial lavage: a molecular tool for lung cancer detection. Cancer Res 61: 1624-1628, 2001. (Pubitemid 34292597)
70. Gazdar AF and Minna JD: Molecular detection of early lung cancer. J Natl Cancer Inst 91: 299-301, 1999. (Pubitemid 29102328)
71. Mulshire JL, Linnoila RI, Jensen SM, et al: Rational targets for early detection of lung cancer. Natl Cancer Inst Monogr: 13183-13190, 1992.
72. Fong KM, Sekido Y and Minna JD: Molecular pathogenesis of lung cancer. J Thorac Cardiovasc Surg 118: 1136-1152, 1999.
73. Ahrendt SA, Chow JT, Xu LH, et al : Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 91: 332-339, 1999. (Pubitemid 29102332)
74. Li C, Chen Z, Xiao Z, et al: Comparative proteomics analysis of human lung squamous carcinoma. Biochem Biophys Res Commun 309: 253-260, 2003. (Pubitemid 36999783)
75. Diederich S and Wormanns D: Impact of low-dose CT on lung cancer screening. Lung Cancer 45: S13-S19, 2004. (Pubitemid 39488166)